Justin Meiklem

BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications

– CDMO program advances to Stage 2 of development agreement valued at $1.125 million -Advancement of sustainable solution for the production of saffron, one of the world’s most valuable and health-promoting botanicals – In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition   Vancouver, British Columbia and […]

BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications Read More »

BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using its Proprietary Botanical Synthesis Platform

Source plant is widely regarded as one of the most valuable fragrance raw materials in the world Stage 2 contract follows successful Stage 1 completion in March 2026 Vancouver, British Columbia and Rehovot, Israel— (May 12, 2026) – BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a leader in Botanical Synthesis technology

BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using its Proprietary Botanical Synthesis Platform Read More »

BioHarvest Sciences Announces Strategic Leadership Transition with Dr. Zaki Rakib Assuming Role of Chief Executive Officer to Accelerate “Two-Lens” Growth Strategy

Ilan Sobel joins Board of Directors with focused mandate on D2C growth.Dr. Zaki Rakib, Co-Founder and Executive Chairman, assumes role of Chief Executive Officer, Integrating R&D, Manufacturing, and Operations under the CDMO. Vancouver, British Columbia and Rehovot, Israel – April 29, 2026 – BioHarvest Sciences Inc. (Nasdaq: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a

BioHarvest Sciences Announces Strategic Leadership Transition with Dr. Zaki Rakib Assuming Role of Chief Executive Officer to Accelerate “Two-Lens” Growth Strategy Read More »

BioHarvest Sciences Announces First-Ever Successful Stable Cell Culture Development of Rare Fragrance-Producing Plant Using Proprietary Botanical Synthesis Platform

CDMO division has successfully completed Stage 1 under a development contract Vancouver, British Columbia and Rehovot, Israel – March 31, 2026 — BioHarvest Sciences Inc. (“BioHarvest” or the “Company”), (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has successfully completed Stage 1

BioHarvest Sciences Announces First-Ever Successful Stable Cell Culture Development of Rare Fragrance-Producing Plant Using Proprietary Botanical Synthesis Platform Read More »

BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results 

FY2025 Revenues were $34.5 million,  up 37% vs previous year. The VINIA brand has achieved the  No.1 resveratrol polyphenol position in the United States Market*. Successful 4Q2025 Institutional-led Financing raised gross proceeds of an oversubscribed  $19.9 million. Cash and cash equivalents of $23 million as of December 31, 2025. Vancouver, British Columbia and Rehovot, Israel

BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results  Read More »

BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026

Vancouver, British Columbia and Rehovot, Israel – March 17, 2026 — BioHarvest Sciences Inc. (“BioHarvest” or the “Company”), (NASDAQ: BHST) (FSE: 8MV0), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company

BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026 Read More »